H.R. 4553 · 116th Congress
Adding Epidemic Diseases to the FDA Priority Review Voucher Program Act
Key: what the circles and colors mean
Each circle is a bill. The ring fills as it moves through Congress:
Under the number: the Yea · Nay count of its final (or latest) recorded vote. On a member's page, the small badge is how that member voted: Y Yea / Aye, N Nay / No, P Present, – Not voting.
Gold and violet are only for Yea and Nay; they never mean a party. A member's party is the letter on their photo.
Never voted on. It didn't reach a floor vote before the 116th Congress ended, so it expired. A bill has to be introduced again to be considered in a new Congress.
D
BoyleSponsor4 cosponsors · 1 D, 3 R
3 signed on when it was introduced; the rest joined later. Cosponsors who withdrew aren't shown.
Adding Epidemic Diseases to the FDA Priority Review Voucher Program Act
What it does: CRS summary · Introduced in House · Sep 27, 2019
Adding Epidemic Diseases to the FDA Priority Review Voucher Program Act
This bill expands the priority-review voucher program for tropical diseases to include Middle East respiratory syndrome, Nipah virus, and Rift Valley fever. A voucher entitles the holder to have a future new drug or biological product application acted upon by the Food and Drug Administration within six months.
Written by the nonpartisan Congressional Research Service. All summary versions on Congress.gov
About this bill and sources
Official title: Adding Epidemic Diseases to the FDA Priority Review Voucher Program Act
Latest action (Sep 30, 2019): Referred to the Subcommittee on Health.
Policy area: Health · Origin: House · Introduced: Sep 27, 2019
Official page on Congress.gov · Bill text (GovInfo) · Status record (XML)
No recorded floor vote found.